<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800877</url>
  </required_header>
  <id_info>
    <org_study_id>OVATION</org_study_id>
    <nct_id>NCT01800877</nct_id>
  </id_info>
  <brief_title>Optimal VAsopressor titraTION Pilot Randomized Controlled Trial</brief_title>
  <acronym>OVATION</acronym>
  <official_title>Optimal Vasopressor Titration Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francois Lamontagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if it is better to give vasopressors to
      patients to maintain a higher blood pressure target versus a lower blood pressure target.
      This study is important because the information we find out will help us know how best to
      administer vasopressors in patients with shock in the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are admitted to the intensive care unit (ICU) commonly suffer from shock, a
      condition that causes life-threatening low blood pressure. Low blood pressure makes it
      difficult for the body to deliver blood to all of its organs. The standard treatment doctors
      in the ICU use for their patients is to give medications that help increase blood pressure.
      These medications are called vasopressors. There can be side effects related to using
      vasopressors. The purpose of this research study is to determine if it is better to give
      vasopressors to patients to maintain a higher blood pressure target versus a lower blood
      pressure target. This study is important because the information we find out will help us
      know how best to administer vasopressors in patients with shock in the ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAP While on Vasopressors</measure>
    <time_frame>While on vasopressors from randomization until 28 days</time_frame>
    <description>The primary feasibility outcome will be the difference in the means of mean arterial pressures (MAP) while on vasopressors and we define acceptable adherence (the threshold for feasibility) by a difference of at least 5 mmHg while on vasopressors (rejecting the null hypothesis of a difference of less than 5 mmHg - see proposed sample size).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypotension</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Liberal Approach</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive Approach</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressors</intervention_name>
    <arm_group_label>Liberal Approach</arm_group_label>
    <arm_group_label>Restrictive Approach</arm_group_label>
    <other_name>phenylephrine</other_name>
    <other_name>dopamine</other_name>
    <other_name>norepinephrine</other_name>
    <other_name>epinephrine</other_name>
    <other_name>vasopressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Who are receiving vasopressors for distributive shock

          2. Who are older than 16 years of age at the time of eligibility.

          3. Who are under the direct care of the ICU team regardless of location.

          4. Who have received a minimum of 30 mL/kg of intravenous fluids (2100 mL for a 70 kg
             patient) before enrolment OR the most responsible physician has good reasons to
             believe that more fluid resuscitation is no longer required and could be harmful.

          5. Who the treating physician believes will need vasopressors for at least 6 hours once
             enrolled.

        Exclusion Criteria:

          1. Have received vasopressors for more than 24 consecutive hours; if vasopressors are
             discontinued for &gt;= 2 hours then restarting vasopressors will constitute a distinct
             vasopressor episode and the clock will be reset.

          2. Are judged by the treating physician to be in obvious cardiogenic shock after an acute
             myocardial infarction (based on new ST segment elevations on ECG or obvious
             echocardiographic findings).

          3. Have obvious haemorrhagic shock as a consequence of a clearly identified source of
             blood loss.

          4. Require vasopressors after cardiac surgery as a result of cardiopulmonary
             bypass-induced hypotension.

          5. Who have a specific indication for catecholamine therapy other than shock (i.e.
             angioedema or intracranial hypertension).

          6. If the attending team has agreed to withhold or withdraw life sustaining care.

          7. Concurrent enrollment in interventional trials that do not meet guidelines (see
             ccctg.ca) for co-enrollment (co-enrollment is permissible if there is no potential
             interaction between the protocols; this will be addressed case by case).

          8. Prior randomization in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Lamontagne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Elizabeth II Hospital</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrooke HSC</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital L'Enfant-Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>February 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2019</results_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Francois Lamontagne</investigator_full_name>
    <investigator_title>Assistant Professor, Universite de Sherbrooke</investigator_title>
  </responsible_party>
  <keyword>hypotension</keyword>
  <keyword>vasopressors</keyword>
  <keyword>titration</keyword>
  <keyword>tissue perfusion</keyword>
  <keyword>organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2013 to August 2014, intensive care units (ICUs) at 11 academic hospitals in Canada and the USA participated in this open-label randomized controlled trial with approval from their local research ethics boards.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Liberal Approach</title>
          <description>In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
Vasopressors</description>
        </group>
        <group group_id="P2">
          <title>Restrictive Approach</title>
          <description>We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
Vasopressors</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liberal Approach</title>
          <description>In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
Vasopressors</description>
        </group>
        <group group_id="B2">
          <title>Restrictive Approach</title>
          <description>We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
Vasopressors</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="13"/>
                    <measurement group_id="B2" value="66" spread="13"/>
                    <measurement group_id="B3" value="65" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MAP While on Vasopressors</title>
        <description>The primary feasibility outcome will be the difference in the means of mean arterial pressures (MAP) while on vasopressors and we define acceptable adherence (the threshold for feasibility) by a difference of at least 5 mmHg while on vasopressors (rejecting the null hypothesis of a difference of less than 5 mmHg - see proposed sample size).</description>
        <time_frame>While on vasopressors from randomization until 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal Approach</title>
            <description>In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
Vasopressors</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Approach</title>
            <description>We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
Vasopressors</description>
          </group>
        </group_list>
        <measure>
          <title>MAP While on Vasopressors</title>
          <description>The primary feasibility outcome will be the difference in the means of mean arterial pressures (MAP) while on vasopressors and we define acceptable adherence (the threshold for feasibility) by a difference of at least 5 mmHg while on vasopressors (rejecting the null hypothesis of a difference of less than 5 mmHg - see proposed sample size).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="5"/>
                    <measurement group_id="O2" value="70" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liberal Approach</title>
          <description>In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
Vasopressors</description>
        </group>
        <group group_id="E2">
          <title>Restrictive Approach</title>
          <description>We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
Vasopressors</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrythmia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastric feeding intolerance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Digit or limb necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Venous thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marie-Hélène Masse</name_or_title>
      <organization>Centre de Recherche du CHUS</organization>
      <phone>819-346-1110 ext 14173</phone>
      <email>marie-helene.masse3@usherbrooke.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

